Overview

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
Phase:
Phase 2
Details
Lead Sponsor:
Galapagos NV